Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s Baraclude (Entecavir) Recommended For First-Line Hep B Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb’s Baraclude (entecavir) recommended for first-line treatment of chronic hepatitis B virus at meeting of FDA’s Antiviral Drugs Advisory Committee. The committee unanimously agrees entecavir has favorable risk/benefit profile despite potential carcinogenicity risks.

You may also be interested in...



FDA Concerns About Baraclude Cancer Risk Tempered By Hepatitis B Virus Oncogenicity

After Carcinogenicity Assessment Committee establishes a potential risk in humans, Bristol proposes 12,500-patient, long-term, postmarketing safety study. Implications and design of the study are a primary focus of reviewers' discussion of hepatitis B agent's safety.

FDA Concerns About Baraclude Cancer Risk Tempered By Hepatitis B Virus Oncogenicity

After Carcinogenicity Assessment Committee establishes a potential risk in humans, Bristol proposes 12,500-patient, long-term, postmarketing safety study. Implications and design of the study are a primary focus of reviewers' discussion of hepatitis B agent's safety.

Bristol-Myers Squibb’s Hepatitis B Therapy Baraclude Will Be Available April 8

Entecavir clears FDA after a six-month priority review. Baraclude labeling includes data showing superior efficacy versus GlaxoSmithKline’s Epivir-HBV. Bristol will detail the product to the 3,500 physicians who treat most U.S. cases of hepatitis B using a Baraclude-specific sales force.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel